€40.10
2.82% day before yesterday
Paris, Aug 22, 05:35 pm CET
ISIN
FR001400Q9V2
Symbol
EXENS

Exosens Target price 2025 - Analyst rating & recommendation

Exosens Classifications & Recommendation:

Buy
81%
Hold
13%
Sell
6%

Exosens Price Target

Target Price €38.76
Price €40.10
Deviation
Number of Estimates 11
11 Analysts have issued a price target Exosens 2026 . The average Exosens target price is €38.76. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 13 Analysts recommend Exosens to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Exosens stock has an average upside potential 2026 of . Most analysts recommend the Exosens stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million € 394.08 479.97
35.04% 21.80%
EBITDA Margin 26.93% 29.87%
1.13% 10.90%
Net Margin 7.79% 16.68%
23.40% 114.25%

11 Analysts have issued a sales forecast Exosens 2025 . The average Exosens sales estimate is

€480m
Unlock
. This is
11.18% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€496m 14.80%
Unlock
, the lowest is
€449m 3.97%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 €394m 35.04%
2025
€480m 21.80%
Unlock
2026
€535m 11.52%
Unlock
2027
€585m 9.35%
Unlock

11 Analysts have issued an Exosens EBITDA forecast 2025. The average Exosens EBITDA estimate is

€143m
Unlock
. This is
12.67% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€155m 21.80%
Unlock
, the lowest is
€123m 3.73%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €106m 36.57%
2025
€143m 35.07%
Unlock
2026
€162m 13.23%
Unlock
2027
€181m 11.75%
Unlock

EBITDA Margin

2024 26.93% 1.13%
2025
29.87% 10.90%
Unlock
2026
30.33% 1.54%
Unlock
2027
30.99% 2.18%
Unlock

10 Exosens Analysts have issued a net profit forecast 2025. The average Exosens net profit estimate is

€80.1m
Unlock
. This is
43.67% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€88.0m 57.87%
Unlock
, the lowest is
€67.9m 21.89%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €30.7m 66.65%
2025
€80.1m 160.98%
Unlock
2026
€95.0m 18.70%
Unlock
2027
€111m 16.61%
Unlock

Net Margin

2024 7.79% 23.40%
2025
16.68% 114.25%
Unlock
2026
17.76% 6.47%
Unlock
2027
18.94% 6.64%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share 0.74 1.58
105.56% 113.51%
P/E 25.43
EV/Sales 4.50

10 Analysts have issued a Exosens forecast for earnings per share. The average Exosens EPS is

€1.58
Unlock
. This is
44.95% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
€1.73 58.72%
Unlock
, the lowest is
€1.34 22.94%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €0.74 105.56%
2025
€1.58 113.51%
Unlock
2026
€1.87 18.35%
Unlock
2027
€2.18 16.58%
Unlock

P/E ratio

Current 36.79 8.98%
2025
25.43 30.88%
Unlock
2026
21.42 15.77%
Unlock
2027
18.37 14.24%
Unlock

Based on analysts' sales estimates for 2025, the Exosens stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.00 152.53%
2025
4.50 10.05%
Unlock
2026
4.03 10.33%
Unlock
2027
3.69 8.55%
Unlock

P/S ratio

Current 4.59 164.65%
2025
4.13 10.06%
Unlock
2026
3.70 10.33%
Unlock
2027
3.38 8.55%
Unlock

Current Exosens Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
STIFEL EUROPE
Locked
Locked
Locked Jul 14 2025
MIDCAP PARTNERS
Locked
Locked
Locked May 18 2025
ODDO BHF
Locked
Locked
Locked Apr 27 2025
ODDO BHF
Locked
Locked
Locked Mar 24 2025
STIFEL EUROPE
Locked
Locked
Locked Mar 12 2025
ODDO BHF
Locked
Locked
Locked Mar 03 2025
Analyst Rating Date
Locked
STIFEL EUROPE:
Locked
Locked
Jul 14 2025
Locked
MIDCAP PARTNERS:
Locked
Locked
May 18 2025
Locked
ODDO BHF:
Locked
Locked
Apr 27 2025
Locked
ODDO BHF:
Locked
Locked
Mar 24 2025
Locked
STIFEL EUROPE:
Locked
Locked
Mar 12 2025
Locked
ODDO BHF:
Locked
Locked
Mar 03 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today